Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Neuroblastoma 8Ganglioneuroblastoma 4Osteosarcoma 2

Interventions

X-Rays 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Phantoms, Imaging 6Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4cixutumumab 3cabozantinib 3Temozolomide 3Leucovorin 3Filgrastim 3Cyclophosphamide 3Cisplatin 3ulixertinib 2tipifarnib 2temsirolimus 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2merphos 2larotrectinib 2ixabepilone 2ivosidenib 2ensartinib 2dinutuximab 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Osteosarcoma × dinutuximab × Clear all
NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 12 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT02484443 2023-10-26

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 15 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡